CoreBone Overview
CoreBone has developed a strong, bioactive coral bone graft for dental and orthopedic indications. The biomimetic bone graft offers a set of bonelike qualities, such as strength, porosity, resorption, and bioactivity, without being derived from human or animal bone. The companys bone graft is made from coral that is cultured in a closely monitored system, providing better control in enriching the graft with silicium and strontium for bioactivity and increased strength. CoreBone has been awarded CE approval, and FDA 510K submission is planned for mid-2017. CoreBone products are CE and ISO 13485 certified.
Cumulative Funding Raised Over Time ($)
$617KFeb 2018
$2.6MJan 2013
$6.3MOct 2021
Latest News
growth-positive
CoreBone Raises $3.7 Million Investment to Commercialize its Bioactive Bone Graft Material for Dental and Orthopedic Treatments & Expand Activity in China
CoreBone, a company that produces bioactive, coral-based bone graft material, has completed an investment round of $3.7 million. The Guangzhou Sino-Israel Biotech Investment Fund invested $3 million in CoreBones Chinese subsidiary, while The Trendlines Group and Agriline invested $700,000. The funds will be used to expand CoreBones global presence, particularly in China. CoreBone develops and sells bioactive bone graft material using cultured coral, eliminating the need for animal or human bone grafts. The investment will accelerate CoreBones sales efforts in China, where the import of foreign human-derived bone grafts is banned. The company aims to fulfill the growing demand for its products in the Chinese market.
Investment
growth-positive
Growing new bone from corals raised in the Israeli desert
Israeli company CoreBone has received CE approval to start selling its bone-graft product made of enhanced coral in Europe for dental and orthopedic procedures. The product is made from corals grown in a closed system using patented technology to provide bioactivity and eliminate biological contamination. CoreBones product offers the best of both worlds, combining the advantages of organic grafts and synthetic grafts. The global markets for orthopedic and dental bone-graft substitutes are expected to reach $3.4 billion and $1 billion, respectively, next year. CoreBones material has been found to have a high rate of bio-integration and connectivity with the host bone compared to leading products in the market. The company has raised about $2 million from public sources and private investors and is planning to launch its products in Europe and Israel.
Customers
growth-positive
Sci-Fi Medicine Sees Corals Turned Into Bone Grafts
Israeli company CoreBone is manufacturing bone grafts from coral grown in the desert for use in orthopedic and dental procedures. The company has developed a coral-based, bioactive bone graft that has all the qualities of a biological bone graft without the risk of contracting diseases. CoreBones bone grafts are expected to cost less than existing options in the orthopedic market. The company plans to begin human trials in selected hospitals in Israel and France before entering the market.
PartnersCustomers
growth-positive
CoreBone Implants Corals As Human Bone Replacements
CoreBone, a company that manufactures bone-replacements from corals, is experiencing growth in the market for bone replacements. The CEO, Ohad Schwartz, discovered the idea for using corals as bone substitutes and approached Professor Itzhak Binderman, who had already worked with corals for bone tissue building. CoreBone is growing corals in a controlled environment to ensure quality and is using a bioactive mineral diet to attract bone cells. The company has conducted successful animal trials and is planning to enter the dental market first, followed by the orthopedic market. They are seeking a $2.5 million investment to expand and develop products for these markets.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.32M |
| Last funding | $3.7M |
| Stage | A |
| Rounds | 3 |
| Investors | 5 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.core-bone.com |
Locations
Misgav, Israel
Photos & Videos
6 item(s)
CoreBone Business
Business models
B2B
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Commerce & RetailDistribution ChannelsDistributorHealthcare & Life SciencesHealthcareProvidersCore Technology
Materials & SubstancesBiologicalsTags (5)
biotechnologymedical-technologiesdentalorthopedicsboneGeographic Markets
ChinaEuropeCoreBone Financials
$6.32M
Total funding
Undisclosed
Capital raised
$3.7M
Last funding
A
Funding stage
3
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$617KFeb 2018
$2.6MJan 2013
$6.3MOct 2021
Private Equity Funding
A Round
Oct 2021
$3.7M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
,
Agriline, The Trendlines Group
Equity crowdfunding
Feb 2018
$617K
ExitValley
Seed
Jan 2013
$2M
The Trendlines Group, Undisclosed Investor(s)
CoreBone Lifecycle
Cumulative Funding Raised Over Time
$617KFeb 2018
$2.6MJan 2013
$6.3MOct 2021
All Events
A Round
Oct 2021
$3.7M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
,
Agriline, The Trendlines Group
Equity crowdfunding
Feb 2018
$617K
ExitValley
Seed
Jan 2013
$2M
The Trendlines Group, Undisclosed Investor(s)
CoreBone News
4 articles
growth-positive
CoreBone Raises $3.7 Million Investment to Commercialize its Bioactive Bone Graft Material for Dental and Orthopedic Treatments & Expand Activity in China
CoreBone, a company that produces bioactive, coral-based bone graft material, has completed an investment round of $3.7 million. The Guangzhou Sino-Israel Biotech Investment Fund invested $3 million in CoreBones Chinese subsidiary, while The Trendlines Group and Agriline invested $700,000. The funds will be used to expand CoreBones global presence, particularly in China. CoreBone develops and sells bioactive bone graft material using cultured coral, eliminating the need for animal or human bone grafts. The investment will accelerate CoreBones sales efforts in China, where the import of foreign human-derived bone grafts is banned. The company aims to fulfill the growing demand for its products in the Chinese market.
Investment
growth-positive
Growing new bone from corals raised in the Israeli desert
Israeli company CoreBone has received CE approval to start selling its bone-graft product made of enhanced coral in Europe for dental and orthopedic procedures. The product is made from corals grown in a closed system using patented technology to provide bioactivity and eliminate biological contamination. CoreBones product offers the best of both worlds, combining the advantages of organic grafts and synthetic grafts. The global markets for orthopedic and dental bone-graft substitutes are expected to reach $3.4 billion and $1 billion, respectively, next year. CoreBones material has been found to have a high rate of bio-integration and connectivity with the host bone compared to leading products in the market. The company has raised about $2 million from public sources and private investors and is planning to launch its products in Europe and Israel.
Customers
growth-positive
Sci-Fi Medicine Sees Corals Turned Into Bone Grafts
Israeli company CoreBone is manufacturing bone grafts from coral grown in the desert for use in orthopedic and dental procedures. The company has developed a coral-based, bioactive bone graft that has all the qualities of a biological bone graft without the risk of contracting diseases. CoreBones bone grafts are expected to cost less than existing options in the orthopedic market. The company plans to begin human trials in selected hospitals in Israel and France before entering the market.
PartnersCustomers
growth-positive
CoreBone Implants Corals As Human Bone Replacements
CoreBone, a company that manufactures bone-replacements from corals, is experiencing growth in the market for bone replacements. The CEO, Ohad Schwartz, discovered the idea for using corals as bone substitutes and approached Professor Itzhak Binderman, who had already worked with corals for bone tissue building. CoreBone is growing corals in a controlled environment to ensure quality and is using a bioactive mineral diet to attract bone cells. The company has conducted successful animal trials and is planning to enter the dental market first, followed by the orthopedic market. They are seeking a $2.5 million investment to expand and develop products for these markets.
InvestmentExpand
CoreBone Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
CoreBone Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Sharon Shapira |
| Registrar ID | 514687151 |
| Crunchbase | corebone |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yotam Maman |
| Updater email | yotamm1988@gmail.com |
| Last update | 2021-10-05T00:00:00.000Z |
| Created | 2014-07-31T00:00:00.000Z |